

Appln. No. 09/744,804
Amdt. dated November 28, 2003

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-16 (cancelled)

17 (Currently amended). A method of treating or preventing the rejection of transplanted organs, tissues or cells which comprises administering to a subject in need thereof an ~~amino terminally truncated or extended~~ (1) a chemokine receptor antagonist for the RANTES receptors selected from the group consisting of Met-RANTES, Leu-RANTES, Gln-RANTES, amino terminally truncated RANTES missing the first two amino acid residues, amino terminally truncated RANTES missing the first five amino acid residues, amino terminally truncated RANTES missing the first six amino acid residues, amino terminally truncated RANTES missing the first seven amino acid residues, amino terminally truncated RANTES missing the first eight amino acid residues, and amino terminally truncated RANTES missing the first nine amino acid residues and (2) a cyclosporin to treat or prevent the rejection of transplanted organs, tissues or cells.

18 (Previously presented). The method according to claim 17, wherein the chemokine receptor antagonist and cyclosporin are administered simultaneously.

Appln. No. 09/744,804
Amdt. dated November 28, 2003

19(Previously presented). The method according to claim 17, wherein the chemokine receptor antagonist and cyclosporin are administered sequentially or separately.

20(Currently amended). The method according to claim 17, wherein the chemokine receptor antagonist is ~~an amino-terminally truncated RANTES~~ Gln-RANTES.

21(Currently amended). The method according to claim 17, wherein the chemokine receptor antagonist is ~~an amino-terminally extended~~ Leu-RANTES.

22(Previously presented). The method according to claim 17, wherein the chemokine receptor antagonist is Met-RANTES.

Claim 23(cancelled)

24(Previously presented). The method according to claim 17, wherein the cyclosporin is cyclosporin A.

25(Previously presented). The method according to claim 24, wherein the chemokine receptor antagonist is Met-RANTES.

26(Previously presented). The method according to claim 25, wherein the rejection treated or prevented is renal allograft transplantation rejection.

Appln. No. 09/744,804
Amdt. dated November 28, 2003

Claims 27 and 28 (Cancelled).

29(Previously presented). The method according to claim 17, wherein the rejection treated or prevented is renal allograft transplantation rejection.

30(Currently amended). A pharmaceutical composition comprising at least one pharmaceutically acceptable excipient and the combination of (1) a chemokine receptor antagonist for the RANTES receptors selected from the group consisting of Met-RANTES, Leu-RANTES, Gln-RANTES, amino terminally truncated RANTES missing the first two amino acid residues, amino terminally truncated RANTES missing the first five amino acid residues, amino terminally truncated RANTES missing the first six amino acid residues, amino terminally truncated RANTES missing the first seven amino acid residues, amino terminally truncated RANTES missing the first eight amino acid residues, and amino acid residues terminally truncated RANTES missing the first nine and (2) a cyclosporin.

31(Previously presented). The pharmaceutical composition according to claim 30, wherein the chemokine receptor antagonist is ~~an amino terminally truncated RANTES~~ Gln-RANTES.

32(Currently amended). The pharmaceutical composition according to claim 30, wherein the chemokine receptor antagonist is ~~an amino terminally extended~~ Leu-RANTES.

Appln. No. 09/744,804
Amdt. dated November 28, 2003

33(Previously presented). The pharmaceutical according to claim 30, wherein the chemokine receptor antagonist is Met-RANTES.

Claim 34(cancelled)

35(Previously presented). The pharmaceutical composition according to claim 30, wherein the cyclosporin is cyclosporin A.

36(Previously presented). The pharmaceutical composition according to claim 35, wherein the chemokine receptor antagonist is Met-RANTES.

Claim 37 (Cancelled).